> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-33/
- Published: 2020-11-22T12:00:00.000Z
- Updated: 2026-09-14T16:37:26.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140060

**Mallinckrodt** has agreed to acquire U.S.-based **Ocera Therapeutics**, a clinical-stage biopharmaceutical company in a deal valued at about $117 million. The transaction gives Mallinckrodt Ocera’s developmental product OCR-002, an ammonia scavenger currently being studied to treat hepatic encephalopathy, a neuropsychiatric syndrome that is associated with hyperammonemia, a complication of acute or chronic liver disease.

**Almac Group**, a contract development and manufacturing organizatio), announced that it will acquire **BioClin Laboratories**, a contract analytical research and development company based in Athlone, Ireland that specializes in GMP pharmaceutical and biopharmaceutical analysis, microbiology testing, and formulation development.

**Owens & Minor** has agreed to buy **Halyard Health**’ssurgical and infection prevention business for about $710 million. Owens & Minor supplies surgical gowns, sterilization wraps, and medical gloves under the Aeroblue, Aerochrome, One-Step, Quick Check and Smart-Fold brands. Halyard makes medical devices that are mostly used for pain management, such a respiratory pumps.

The Netherlands-based medical device-focused **CRO Factory** has acquired **Milestone Research Organization**, which has expertise in orthopedics, neurological and IVD clinical trials. The addition of San Diego-based Milestone builds on Factory’s existing U.S. presence in Austin, TX and Princeton, NJ.